These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 29868153)
1. Relationship between tumour size and response to neoadjuvant chemotherapy among breast cancer patients in a tertiary center in Nigeria. Samuel O; Olayide A; Ganiyu R; Olufemi H; Halimat A Malawi Med J; 2018 Mar; 30(1):13-16. PubMed ID: 29868153 [TBL] [Abstract][Full Text] [Related]
2. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Reinisch M; Huober J; von Minckwitz G; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Schneeweiss A; Rhiem K; Lederer B; Untch M; Nekljudova V V; Loibl S Breast; 2017 Apr; 32():73-78. PubMed ID: 28063331 [TBL] [Abstract][Full Text] [Related]
3. Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer. Rašić A; Sofić A; Bešlija S; Rašić I; Hasanbegović B Med Glas (Zenica); 2019 Feb; 16(1):77-82. PubMed ID: 30256061 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers. Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326 [TBL] [Abstract][Full Text] [Related]
5. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients]. Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital. Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250 [TBL] [Abstract][Full Text] [Related]
7. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy? Coelho RC; Da Silva FML; Do Carmo IML; Bonaccorsi BV; Hahn SM; Faroni LD Breast; 2017 Feb; 31():192-196. PubMed ID: 27889595 [TBL] [Abstract][Full Text] [Related]
8. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy. Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233 [TBL] [Abstract][Full Text] [Related]
9. Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment. Fatayer H; Sharma N; Manuel D; Kim B; Keding A; Perren T; Velikova G; Lansdown M; Shaaban AM; Dall B Eur J Surg Oncol; 2016 Jul; 42(7):965-72. PubMed ID: 27260848 [TBL] [Abstract][Full Text] [Related]
10. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Estévez LG; Gradishar WJ Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677 [TBL] [Abstract][Full Text] [Related]
11. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Goble S; Bear HD Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604 [TBL] [Abstract][Full Text] [Related]
12. Multi-parametric MRI in the early prediction of response to neo-adjuvant chemotherapy in breast cancer: Value of non-modelled parameters. O'Flynn EA; Collins D; D'Arcy J; Schmidt M; de Souza NM Eur J Radiol; 2016 Apr; 85(4):837-42. PubMed ID: 26971432 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of neoadjuvant chemotherapy in down staging locally advanced pre-menopausal breast cancer in Eastern Nigeria: is four courses adequate? Egwuonwu OA; Anyanwu SN; Nwofor AM J Cancer Res Ther; 2013; 9(4):638-43. PubMed ID: 24518709 [TBL] [Abstract][Full Text] [Related]
14. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090 [TBL] [Abstract][Full Text] [Related]
15. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital. Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Tan QX; Qin QH; Yang WP; Mo QG; Wei CY Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769 [TBL] [Abstract][Full Text] [Related]
17. The impact of neoadjuvant chemotherapy on patients with locally advanced breast cancer in a Nigerian semiurban teaching hospital: a single-center descriptive study. Arowolo OA; Akinkuolie AA; Lawal OO; Alatise OI; Salako AA; Adisa AO World J Surg; 2010 Aug; 34(8):1771-8. PubMed ID: 20467742 [TBL] [Abstract][Full Text] [Related]
18. Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis. Tran WT; Gangeh MJ; Sannachi L; Chin L; Watkins E; Bruni SG; Rastegar RF; Curpen B; Trudeau M; Gandhi S; Yaffe M; Slodkowska E; Childs C; Sadeghi-Naini A; Czarnota GJ Br J Cancer; 2017 May; 116(10):1329-1339. PubMed ID: 28419079 [TBL] [Abstract][Full Text] [Related]
19. Apoptosis induced by neoadjuvant chemotherapy in breast cancer. Tiezzi DG; De Andrade JM; Cândido dos Reis FJ; Marana HR; Ribeiro-Silva A; Tiezzi MG; Pereira AP Pathology; 2006 Feb; 38(1):21-7. PubMed ID: 16484003 [TBL] [Abstract][Full Text] [Related]
20. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer. Vriens BE; de Vries B; Lobbes MB; van Gastel SM; van den Berkmortel FW; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Smidt ML; Peer PG; Aarts MJ; Tjan-Heijnen VC; Eur J Cancer; 2016 Jan; 52():67-76. PubMed ID: 26650831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]